Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:17:25 2024-07-17 am EDT			5-day change	1st Jan Change
24.8 ^USD	-2.29%		+15.51%	-20.39%

Jul. 01	Arcturus Therapeutics Updates Ornithine Transcarbamylase Deficiency, Cystic Fibrosis Programs	MT
Jul. 01	Arcturus Therapeutics Holdings Inc. Provides Updates for Ornithine Transcarbamylase Deficiency and Cystic Fibrosis (CF) Programs	CI

Arcturus Therapeutics Ltd. Announces Resignation of Orli Tori as Member of the Board of Directors

January 24, 2018 at 08:41 am EST

Effective January 23, 2018, Orli Tori resigned as a member of the board of directors of Arcturus Therapeutics Ltd. Ms. Tori’s resignation was for personal reasons and not due to any disagreement with the company.

Latest news about Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Updates Ornithine Transcarbamylase Deficiency, Cystic Fibrosis Programs	Jul. 01	MT
Arcturus Therapeutics Holdings Inc. Provides Updates for Ornithine Transcarbamylase Deficiency and Cystic Fibrosis (CF) Programs	Jul. 01	CI
Arcturus Therapeutics Holdings Inc. Appoints Moncef Slaoui, Ph.D., to Board of Directors	Jun. 20	CI
Arcturus Therapeutics Holdings Insider Sold Shares Worth $1,601,500, According to a Recent SEC Filing	Jun. 14	MT
Transcript : Arcturus Therapeutics Holdings Inc. - Shareholder/Analyst Call	Jun. 14
Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble	Jun. 07	MT
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference	Jun. 07	CI
Arcturus Therapeutics Holdings Insider Sold Shares Worth $1,040,234, According to a Recent SEC Filing	Jun. 04	MT
Arcturus Therapeutics Holdings Inc. Announces Positive Development for Cystic Fibrosis Program	May. 28	CI
Achilles Therapeutics Collaborating With Arcturus Therapeutics to Evaluate mRNA Personalized Cancer Vaccines	May. 22	MT
Achilles Therapeutics plc Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines	May. 22	CI
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine	May. 20	CI
Transcript : Arcturus Therapeutics Holdings Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q1 Revenue $38M, vs. Street Est of $17.7M	May. 08	MT
Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing	Mar. 27	MT
Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	Mar. 21	MT
Transcript : Arcturus Therapeutics Holdings Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:45 AM	Mar. 14
Canaccord Genuity Adjusts Arcturus Therapeutics Holdings' PT to $87 From $81, Maintains Buy Rating	Mar. 11	MT
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $58 From $45, Maintains Overweight Rating	Mar. 08	MT
Transcript : Arcturus Therapeutics Holdings Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Arcturus Therapeutics Swings to Q4 Net Loss, Revenue Drops	Mar. 07	MT
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q4 Revenue $34M, vs. Street Est of $37.9M	Mar. 07	MT
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 07	CI
Arcturus Therapeutics Holdings Inc. Announces Executive Changes	Feb. 23	CI

Chart Arcturus Therapeutics Holdings Inc.

Duration

Period

Chart Arcturus Therapeutics Holdings Inc.

More charts

Company Profile

Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

Sector

Biotechnology & Medical Research

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Arcturus Therapeutics Holdings Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25.38 USD

Average target price

74.75 USD

Spread / Average Target

+194.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARCTURUS THERAPEUTICS HOLDINGS INC.	-20.39%	684M
MODERNA, INC.	+24.09%	47.96B
IQVIA HOLDINGS INC.	+2.06%	42.45B
LONZA GROUP AG	+44.59%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+27.97%	31.6B
ICON PUBLIC LIMITED COMPANY	+21.70%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+52.09%	14.56B
MEDPACE HOLDINGS, INC.	+49.34%	14.14B
BIO-TECHNE CORPORATION	+3.50%	12.58B

Other Biotechnology & Medical Research